Non-small cell lung cancer

News

ASCO26: Ivonescimab improves survival in NSCLC

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.

News

Dizal breaks new ground for EGFR drugs in lung cancer

Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.

News

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

News

Hernexeos box, two pills, and pill bottle

Boehringer gets FDA's second 'national priority' approval

Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.

News

FDA starts review of Summit's VEGFxPD-1 bispecific

Summit moves ahead in the race to bring a VEGFxPD-(L)1 drug to market, after the FDA started a review of ivonescimab in lung cancer.

ASCO26: Ivonescimab improves survival in NSCLC

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

Dizal breaks new ground for EGFR drugs in lung cancer

Immutep investors spooked by LAG-3 failure in lung cancer

Boehringer gets FDA's second 'national priority' approval

FDA starts review of Summit's VEGFxPD-1 bispecific

UK backs start-up Potential Sciences' AI-powered drug hunt

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks